BRD4 and melanoma: Using the TCGA skin cutaneous melanoma dataset and biopsies from 54 patients to search for new targets to treat NRAS‐mutant melanoma, the authors discovered that BRD4 expression was significantly elevated in tumor cells and correlated with poor survival.